Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026
<p>Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagement Results support continued clinical development of INI-4001 as a potential monotherapy and in combination with other cancer treatments MISSOULA, Mont., Nov. 6, 2026...</p>
Read original article ↗
Related Articles
KPop Demon Hunters on 4K Blu-ray costs less than a month of Netflix Premium
Buying the 4K Blu-ray disc version of KPop Demon Hunters was already going to be a wise idea for some people, especially
Graybar Makes $100,000 Donation to Junior Achievement of Greater St. Louis
Three-Year Sponsorship of JA Trades Supports the Next Generation of Skilled Trades Professionals ST. LOUIS, Nov. 6, 2026
The Verge’s 2026 holiday gift guide
Gift-giving isn't just about grabbing something solid under a determined spending limit. It's an expression of love, a w
Fideltronik starts construction of new production hall
Polish EMS provider Fideltronik is building a new production hall at its headquarters in Sucha Beskidzka. The 7,500 squa